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Abstract
Background: Delayed vaccinations increase the risk for vaccine preventable diseases (VPDs). Monitoring of delayed
vaccinations by using a national immunisation registry has not been studied in countries recommending a two-
dose (3 and 5 months of age) primary series of e.g., pertussis vaccine. Surveillance/monitoring of all vaccinations
may improve vaccination programmes functioning.
Methods: We obtained information from the Norwegian immunisation registry (SYSVAK) on all programme
vaccinations received at age up to 730 days in children born in 2010 (n = 63,382). Timely vaccinations were received
up to 7 days after the recommended age. Vaccinations were considered delayed if they were received more than
one month after the recommended age in the schedule.
Results: In vaccinated children, timely administration of the subsequent three doses of pertussis and one dose of
measles occurred in 73.8, 47.6, 53.6 and 43.5 % respectively. Delay for one or more programme vaccinations
(diphtheria, tetanus, pertussis, polio, Haemophilus influenza type B, invasive pneumococcal disease, measles, mumps
or rubella) was present in 28,336 (44.7 %) children. Among those who were delayed the mean duration was
139 days. The proportion of children that had vaccinations delayed differed among counties (range 37.4 %–57.8 %).
Immigrant children were more frequently delayed 52.3 % vs. 43.1 %, RR 1.21 (95 % CI 1.19, 1.24). Children scheduled
for vaccines in the summer holiday month (July) were more frequently delayed than others (1st dose pertussis
vaccine 6.5 % vs. 3.9 % RR 1.65 (95 % CI 1.48, 1.85). Priming against pertussis (2nd dose), pneumococcal (2nd dose)
and measles (1st dose) was delayed in 16.8, 18.6 and 29.3 % respectively.
Conclusion: Vaccinations were frequently delayed. Delayed vaccinations differed among counties and occurred
more frequently during the summer vacation (July) and in the immigrant population. Monitoring improves
programme surveillance and may be used on an annual basis.
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Background
The infant morbidity of pertussis and invasive
pneumococcal disease (IPD) is high. Measles continues
to be a risk for young children as long as the disease
has not been eradicated. Vaccinations are essential in
preventing diseases [1].
To achieve early protection the first dose of pertussis
and pneumococcal vaccines is recommended at 6 weeks
to 3 months of age followed by additional dose(s) for
primary immunisation and a booster dose to maintain
protection (i.e., 3 priming doses + 1 booster (3 + 1 sched-
ule) or 2 priming doses + 1 booster (2 + 1 schedule)).
The first dose of measles vaccine is recommended from
9 months of age or early in the 2nd year of life [2, 3].
The variation in schedules among countries may depend
on immunisation strategies and well-child services [2].
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Vaccination coverage at age 2 years is often used to
measure vaccination programme performance. However,
it does not reflect whether children are appropriately
protected at all times according to the national schedule.
In Norway, vaccine preventable diseases (VPD) occur in
children delayed for vaccinations [4, 5]. Results from a
Swedish study indicate lower incidence of pertussis if
the first vaccinations occurred on time [6]. The need for
early and timely pertussis vaccination has recently been
highlighted by the WHO [7].
Reports of considerable vaccination delay in Europe,
Australia and the US have been published, but data are
limited for a 2 + 1 schedule as used in Norway [8–10].
Monitoring of delay has been suggested [9]. Monitoring
may identify obstacles and areas of improvement.
Norway uses a national immunisation registry and re-
ports high vaccination coverage at age 2 years (≥93 %
national, ≥ 85 % county); however the proportion and
duration of delayed vaccinations are unknown [11, 12].
Also, because a rota virus vaccine with age restriction
was introduced in Norway in 2014, a system for moni-
toring timely immunisation is planned.
The aim of this study was to describe deviations from
the Norwegian vaccination recommendations with a
special focus on delayed vaccinations in children aged
< 2 years. This was assessed by using the national im-
munisation registry that today is used for annual vac-
cination coverage publications.
Methods
The Norwegian infant vaccination programme
Until September 2014, the Norwegian vaccination
programme for children aged ≤ 2 years included vaccines
against 9 target diseases for all children plus 2 extra
(BCG +Hepatitis B) for risk groups (Table 1). Vaccines
against diphtheria (D), tetanus (T), pertussis (acellular(aP)),
polio (IPV) and Haemophilus influenzae type b (Hib) are
often administered in pentavalent combination vaccines
with two doses at 3 and 5 months as priming and with an
early booster at 11–12 months of age. A vaccine against in-
vasive pneumococcal disease (IPD) is administered at the
same ages. The first dose of vaccine against measles,
mumps and rubella (MMR) is offered at 15 months of age.
Hepatitis B vaccine is offered in early childhood where a
parent originates from a non-low endemic hepatitis B
country or if a family member is infected with hepatitis B.
The Bacillus Calmette-Guérin (BCG) vaccine is recom-
mended if a parent originates from a country with high
prevalence of tuberculosis [13]. All Norwegian municipal-
ities (n = 429) are obliged by law to provide well-baby clinic
services. The services, including immunisations, follow na-
tional recommendations, but are flexible for each child.
Well child visits are provided by nurses and doctors. Vacci-
nations are mainly provided by public health nurses. All
services are voluntary and free of charge. The proportion of
programme vaccinations provided outside the well-baby
clinics is unknown, but is probably very small.
National immunisation registry
The Norwegian immunisation registry (SYSVAK) is a na-
tional registry that has been nationwide since 1995. The
principal objective is to ensure that all children are of-
fered adequate vaccination. It is mandatory for vaccina-
tors to report all administered programme vaccines to
SYSVAK. It is recommended to report previous doses
e.g., vaccinations administered abroad. Notifications of
vaccinations from the well-baby clinics are electronically
transferred from the patient record systems to SYSVAK.
Notifications on paper are also accepted. Information
available in SYSVAK includes personal identification
number, date of birth, sex, vaccine, date of vaccination,
status of residency and municipality. Vaccination cover-
age at age 2 years is published annually [12].
Table 1 The Norwegian Vaccination Programme during 2010–2012, aged < 2 years
Age (months) Target disease Vaccine Number of injections
3 Diphtheria, tetanus, pertussis, polio,
Haemophilus influenza type b
Infanrix-Polio + Hib® (GSK), Prevenar®a (Pfizer) 2
Invasive pneumococcal disease
5 Diphtheria, tetanus, pertussis, polio,
Haemophilus influenza type b
Infanrix-Polio + Hib® (GSK), Prevenar®a (Pfizer) 2
Invasive pneumococcal disease
12 Diphtheria, tetanus, pertussis, polio,
Haemophilus influenza type b
Infanrix-Polio + Hib® (GSK) Prevenar®a (Pfizer) 2
Invasive pneumococcal disease
15 Measles,mumps,rubella M-M-RVaxpro® (Sanofi Pasteur MSD) 1
From early age Hepatitis Bb Engerix-B® (GSK) varies
Tuberculosisb BCG-SSI® 1
aChange from Prevenar 7 to Prevenar 13, April 2011; bRisk groups
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Study population
We extracted information from SYSVAK on all programme
vaccinations received at age ≤ 730 days (up until 2 years of
age) in children born in 2010. Data was collected May 23rd
2013. We included children with permanent residency and
a personal identification number that had at least one vac-
cination registered (n = 61,889). We examined vaccinations
against 11 VPDs irrespective of the use of mono/combin-
ation vaccines or brand names. If more than one vaccin-
ation for the same target disease were recorded on the
same day, this was regarded as a typing error and only one
vaccination was counted. We also included vaccine doses
administered earlier than the recommended age.
The number of children aged 2 years (residents with
personal identification number) in the Norwegian
Population Registry (NPR) as of December 31st 2012
was n = 63,382 [11]. Thus, the number of children that
did not receive any documented programme vaccines
was 1493 (2.4 %).
Definition of timely and delayed immunisations
We classified the recommended age to end at the great-
est number of days that could equal the given number of
months (3 months = 92 days, 5 months = 153 days,
12 months = 365 days and 15 months = 457 days).
Timely vaccinations were calculated for vaccinated
children receiving vaccinations ≤ 7 days after the rec-
ommended age. This was done to have a more precise
estimate for when vaccines were administered accord-
ing to schedule.
Delay was defined similarly to what was done by
Luman et al. [8]. A vaccine was defined as delayed if it
was received later than 1 month (31 days) after the rec-
ommended age. Delay was counted in days and started
at age 124 days for vaccines due at 3 months, at age
185 days for vaccines due at 5 months, at age 397 days
for vaccines due at 12 months and at age 489 days for
vaccines due at 15 months. Delay was counted until re-
ceipt of the vaccine or until the child was 730 days,
whichever came first. For each of the 9 target diseases
we calculated the cumulative delay for all recommended
doses, the number of days on which at least one dose
was delayed. We did not count delay for the two add-
itional vaccines that are only recommended to risk
groups (Hepatitis B and BCG).
For example, suppose a child is given 1st dose of per-
tussis vaccine (due at 3 months) at age 210 days, 2nd
dose (due at 5 months) at age 293 days and 3rd dose
(due at 12 months) at 518 days. The 1st dose is delayed
87 days, the 2nd dose is delayed 109 days and the 3rd is
delayed 122 days. The cumulative delay for pertussis
vaccine is 292 days, since days for which both 1st and
2nd doses are delayed (26 days, ages 185 to 210) are only
counted once. We included all doses, but due to
Norwegian recommendations regarding protection [13],
delay was not counted for 2nd and 3rd dose of Hib vac-
cine if the 1st dose was given at age ≥ 365 days. If
pneumococcal vaccine 1st dose was given ≥ 365 days,
delay was not counted for the 3rd dose.
Finally, we calculated delay for the complete series, de-
fined as number of days of which at least one vaccine was
delayed. Since delay for different vaccines may overlap,
delay for the complete series may be smaller than the sum
of delays for each individual vaccine. Delay was cate-
gorised as 0, 1–7, 8–30, 31–90, 91–180 or > 180 days.
Analysis
Vaccination coverage was calculated as the number of
children fully vaccinated at age ≤ 730 days divided by the
number of resident children born in 2010 aged 2 years
registered in the NPR as of December 31st 2012 (national
level, n = 63,382) [11]. In addition we calculated vaccin-
ation coverage for the first tree doses of pertussis and
pneumococcal vaccinations. Similarly, the proportion of
children with delayed vaccinations was found by dividing
the number of children with delay by the population in
the NPR. We presumed that children without any
programme vaccines in SYSVAK were unvaccinated and
thereby had maximum delay for all vaccines. Since we did
not have any information on the children not registered in
SYSVAK, they were not included when we assessed delay
by sex or county of residence. Vaccinated children with
unknown county of residence (n = 43) were excluded from
the comparison among the 19 Norwegian counties. BCG
vaccinated children were considered immigrants, as this
vaccine is recommended only if a parent originates from a
country with high prevalence of tuberculosis.
To study whether delay was more likely among immi-
grant children than others, we calculated risk ratios and
risk differences from frequency tables with corresponding
95 % confidence intervals (CIs). As children resident in
Norway may follow other International vaccination sched-
ules deviating from the official Norwegian guidelines we
examined the number of pertussis and hepatitis B doses
administered in the immigrant and non-immigrant popu-
lations. We furthermore compared delay among children
scheduled for vaccines in July and children scheduled for
vaccination in any other month. Public services and
kindergartens may have limited opening hours and ser-
vices in July as this is the main summer vacation month in
Norway. The scheduled month was based on month of
birth. These analyses included only children registered in
SYSVAK, since we did not have information on date of
birth for those not registered in SYSVAK. All analyses
were performed with STATA/SE 13.0 (StataCorp, College
Station, Texas, USA).
The study was approved by the Regional Committee
for Medical and Health Research Ethics, Southeast
Riise et al. BMC Pediatrics  (2015) 15:180 Page 3 of 8
Norway. The committee found it acceptable that in-




Figure 1 shows the cumulative distribution of age at vac-
cination for pertussis and measles. The proportion of
vaccinated children who were vaccinated ≤ 7 days after
the recommended age was 73.8 % for the 1st dose of per-
tussis vaccine, 47.6 % for the 2nd dose of pertussis vac-
cine, 53.6 % for the 3rd dose of pertussis vaccine and
43.5 % for measles vaccine. Few children received prim-
ing doses of pertussis (1st and 2nd dose) or the 1st dose
of measles earlier than the recommended age. Of the
children who received pertussis vaccination, the proportion
who received pneumococcal vaccine (given as a separate in-
jection) on the same date was 97.1 % for the 1st dose,
96.5 % for the 2nd dose, and 96.2 % for the 3rd dose. Results
for pneumococcal vaccination were therefore similar to re-
sults for pertussis “Additional file 1”.
Delayed vaccinations
Delay for ≥ 1 programme vaccination was present in
28,336 of 63,382 (44.7 %) children (Table 2). Among
those who were delayed the mean duration was 139 days
(median 36 days). Of those who had vaccinations de-
layed, 7401 (26.1 %) were delayed ≥ 6 months. Vaccin-
ation coverage for VPDs was 93.1–95.7 % (complete
programme 90.2 %).
The proportion of children delayed for pertussis vac-
cination increased by subsequent doses and the cumula-
tive delay was higher for the series of 3 doses than delay
for the 3rd dose (1st dose 6.4 %, 2nd dose 16.8 %, 3rd dose
20.1 %, series of 3 doses 27.6 %). The proportion of
children delayed for primary pneumococcal and mea-
sles vaccination was 18.6 and 29.2 %, respectively. Up
to 3 months delay was more frequent for vaccination
against measles than for the primary pertussis vaccin-
ation, 20.0 % vs. 12.1 %, respectively. Children delayed
for pertussis, 1st dose, were more likely to be delayed
for measles vaccination compared to others, 70.8 % vs.
26.3 % RR 2.69 (95 % CI 2.63, 2.75).
The proportion with delay did not differ by gender (boys
43.7 % vs. girls 43.0 % for the complete series). On county
level, 37.4–57.8 % of children were delayed for ≥ 1
programme vaccination (median delay, range 23–42 days;
Fig. 2). The two counties (Troms and Vestfold) with the
highest proportion delayed vaccinations had vaccination
coverage at 2 years ≥ 89 % for the complete series. When
we compare the counties with highest (Vestfold) and low-
est (Oppland) proportion of delayed vaccinations the im-
migrant population was 15.8 % vs 9.7 %, the proportion
living in urban settlements was 85.3 % vs. 57.1 % and the
proportion of adult higher education was 25.5 % vs.
21.5 % respectively [14].
Summer, delayed vaccinations
Children who according to month of birth were sched-
uled for vaccines in July were more often delayed than
others: 1st dose pertussis vaccine 6.5 % vs. 3.9 %, RR 1.65
(95 % CI 1.48, 1.85); 1st dose pneumococcal vaccine
8.3 % vs. 4.4 %, RR 1.49 (95 % CI 1.35, 1.64); 1st dose
measles vaccine 40.8 % vs. 26.3 %, RR 1.56 (95 % CI
1.50, 1.61) (Table 3).
Immigrants, deviations and delayed vaccinations
Immigrant children were more delayed for the complete
programme than others 52.3 % vs. 43.1 %, respectively,
RR 1.21 (95 % CI 1.19, 1.24) and particularly for
pneumococcal vaccination (38.7 % vs. 27.6 % RR 1.41
(95 % CI 1.37,1.44) (Table 4). Four or more doses pertus-
sis vaccine and ≥ 3 doses hepatitis B vaccine were more
frequently administered to immigrants than to non-
Fig. 1 Cumulative distribution of age at vaccination. Pertussis: 1st dose n = 61,703, 2nd dose n = 61,316, 3rd dose 60,153, measles: n = 59,070
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immigrants 6.3 % vs. 1.1 % RR 5.7 (95 % CI 5.1,6.4), and
89.3 % vs. 2.9 % RR 30.5 (95 % CI 29.0,32.1) respectively.
Discussion
This study documents that 45 % of all children aged ≤
730 days received at least one vaccination later than rec-
ommended. Vaccination coverage at age 2 years was ac-
ceptable and above 93 % for vaccines against 9 target
diseases. Furthermore, the proportions that were delayed
for the complete series differed among counties, whereas
overall coverage did not differ among counties. Delayed
vaccinations occurred more frequently during the main
vacation month of July and in the immigrant population.
Delayed vaccinations in approximately 45 % of children
for the complete series is similar to findings in a recent
American survey by Glanz (49 %), but less than the 74 %
found in a previous American survey by Luman [8, 15].
These two and our study used a similar definition for de-
layed vaccinations. This shows that although different
schedules and data sources were used, delay for the
complete series is a common phenomenon. Moreover,
since a considerable proportion of children have their
vaccines delayed, this should be a public health concern.
Table 2 Vaccination delay and coverage during first 2 years of life among children born 2010, n = 63,382
Children with delay 1–7 days 8–30 days 31–90 days 91–180 days >180 days If delayed, days Vaccinated < 2 years
n % n % n % n % n % n % p25 p50 p75 n %
Pertussisa 17,471 27.6 4025 6.4 5507 8.7 3115 4.9 1002 1.6 3822 6.0 8 25 116 60,153 94.9
1st dose 4070 6.4 640 1.0 724 1.1 548 0.9 112 0.2 2046 3.2 15 192 607 61,703 97.4
2nd dose 10,622 16.8 2923 4.6 3465 5.5 1278 2.0 369 0.6 2587 4.1 7 19 171 61,316 96.7
3rd dose (booster) 12,755 20.1 2265 3.6 3791 6.0 2538 4.0 677 1.1 3484 5.5 11 34 334 60,153 94.9
Pneumococcala,b 18,674 29.5 4015 6.3 5529 8.7 3167 5.0 1080 1.7 4883 7.7 9 29 227 59,377 93.7
1st dose 5085 8.0 660 1.0 775 1.2 627 1.0 171 0.3 2852 4.5 23 294 607 61,119 96.4
2nd dose 11,775 18.6 2934 4.6 3519 5.6 1369 2.2 443 0.7 3510 5.5 8 23 309 60,652 95.7
3rd dose (booster) 13,912 21.9 2266 3.6 3802 6.0 2662 4.2 838 1.3 4344 6.9 12 42 334 59,156 93.3
Diphteriaa 17,460 27.5 4024 6.5 5507 8.9 3117 5.0 1001 1.6 2318 3.7 8 25 116 60,162 94.9
Tetanusa 17,458 27.5 4024 6.3 5506 8.7 3119 4.9 1003 1.6 3806 6.0 8 25 116 60,174 94.9
Polioa 17,460 27.5 4021 6.3 5501 8.7 3114 4.9 1006 1.6 3818 6.0 8 25 116 60,148 94.9
Hiba,c 17,692 27.9 4015 6.3 5484 8.7 3102 4.9 1003 1.6 4088 6.4 9 26 134 60,614 95.6
Measles 18,492 29.2 3067 4.8 5511 8.7 4124 6.5 1203 1.9 4587 7.2 12 36 174 59,070 93.2
Mumps 18,573 29.3 3071 4.8 5517 8.7 4136 6.5 1215 1.9 4634 7.3 12 36 178 59,026 93.1
Rubella 18,565 29.3 3070 4.8 5517 8.7 4133 6.5 1214 1.9 4631 7.3 12 36 178 59,028 93.1
Complete series 28,336 44.7 5040 8.0 8072 12.7 5761 9.1 2070 3.3 7393 11.7 11 36 209 57,202 90.2
aCummulative delay for the first 3 doses
bIf pneumococcal vaccine 1st dose was given after age 365 days, delay was not counted for 3rd dose
cIf Hib vaccine 1st dose was given after age 365 days, delay was not counted for the 2nd and 3rd dose
Fig. 2 Vaccination coverage and delayed vaccinations by county in children aged < 2 years, born 2010, Norway, (n=61846). Legend: Complete series:
Three doses: diphtheria, tetanus, pertussis, polio, haemophilus influenza type B (only 1 dose if 1st dose given at age ≥ 365 days), pneumococcal
(only 2 doses if 1st dose given at age ≥ 365 days), 1 dose: measles, mumps, rubella vaccines. Vaccination coverage, proportion vaccinated at
age 2 years. Delay: vaccination administered ≥ 1 month after due date
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Most children in our study were delayed for a short
period of time (median 36 days). Around 26 % of those
delayed were delayed for ≥ 6 months. Due to the present
Norwegian epidemiological situation, long delay for per-
tussis immunisation is a greater concern than long delay
for measles vaccination. The duration of delay was lon-
ger in one American study [8], where the median delay
was 126 days and 37 % had long delay.
Delayed priming against pertussis occurred in 17 %.
This is less than what has been found in other countries
including Flandern (Belgium) [9, 10, 16]. Other studies
have consistently found that delay increases by number of
doses [8–10]. Compared to a three dose priming schedule,
the two dose priming schedule used in Norway and some
other European countries has the benefit of less immunisa-
tion visits and thereby theoretically fewer options for
Table 3 Vaccinations scheduled in July vs. vaccinations scheduled all other months, n = 61,889
Scheduled July Scheduled all other months RR (95 % CI) RD (95 % CI)
Pertussis, delay
1st dose, n (%) 335 (6.5) 2242 (3.9) 1.65 (1.48, 1.85) 2.6 (1.9, 3.3)
2nd dose, n (%) 877 (18.3) 8252 (14.5) 1.27 (1.19, 1.35) 3.8 (2.7, 5.0)
3rd dose, n (%) 1604 (28.6) 9658 (17.2) 1.67 (1.59, 1.74) 11.4 (10.2, 12.6)
Pneumococcal, delay
1st dose 426 (8.3) 3166 (5.6) 1.49 (1.35, 1.64) 2.7 (1.9, 3.5)
2nd dose 972 (20.3) 9310 (16.3) 1.24 (1.17, 1.32) 4.0 (2.8, 5.2)
3rd dose 1676 (29.9) 10,743 (19.1) 1.56 (1.50, 1.63) 10.8 (9.5, 12.0)
Measles, delay
1st dose, n (%) 2095 (40.8) 14,904 (26.3) 1.56 (1.50, 1.61) 14.6 (13.2, 16.0)
RR relative risk, RD risk difference (%), CI confidence interval
Table 4 Vaccinations and delayed vaccinations in immigrants vs. nonimmigrants, born 2010, Norway, n = 63,382
Immigranta Non-immigrant RR (95 % CI) RD (95 % CI)
(n = 10,773) (n = 52,609)
Complete seriesb
Vaccinated 9510 (88.3) 47,692 (90.7) 0.97 (0.97, 0.98) −2.4 (−3.0, −1.7)
Delayed, n (%) 5638 (52.3) 22,698 (43.1) 1.21 (1.19, 1.24) 9.2 (8.2, 10.2)
If delayed, no of days, median (25p, 75 p) 50 (15, 242) 34 (11, 180)
Pertussis
≥ 3rd dose, n (%) 10,382 (96.4) 49,771 (94.6) 1.02 (1.01, 1.02) 1.8 (1.4, 2.2)
≥ 4doses, n (%) 680 (6.3) 579 (1.1) 5.7 (5.1, 6.4) 5.2 (4.7, 5.7)
Delayed, n (%) 3519 (32.7) 13,952 (26.5) 1.23 (1.19, 1.27) 6.1 (5.2, 7.1)
If delayed, no of days, median (25p, 75 p) 27 (9, 95) 14 (8, 128.5)
Pneumococcal
Vaccinated, n (%) 9958 (92.4) 49,419 (93.9) 0.98 (0.98, 0.99) −1.5 (−2.0, −0.9)
Delayed, n (%) 4174 (38.7) 14,500 (27.6) 1.41 (1.37, 1.44) 11.1 (10.2, 12.2)
If delayed, no of days, median (25p, 75 p) 41 (11, 285) 26 (9, 195)
Measles
1st dose, n (%) 10,081 (93.6) 48,989 (93.1) 1.00 (1.00, 1.01) 0.5 (0.0, 0.9)
Delayed, n (%) 3221 (29.9) 15,271 (29.0) 1.11 (1.07, 1.15) 0.9 (0.0, 1.8)
If delayed no of days, median (25p, 75 p) 38 (13, 148) 35 (12, 186)
Hepatitis B
≥ 3rd dose, n (%) 3rd dosed dose, no (%) 9620 (89.3) 1540 (2.9) 30.5(29.0,-32.1) 86.4 (85.8, 87.0)
aImmigrants was defined as children registered with BCG vaccination
bThree doses of diphtheria, tetanus, pertussis, polio, haemophilus influenza type B (only 1 dose if 1st dose given at age ≥ 365 days), pneumococcal (only 2 doses if
1st dose given at age ≥ 365 days)and one dose of measles, mumps, rubella vaccines
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delayed vaccinations. A Swedish study found that pertussis
vaccination has a protective effect already after the first and
second dose. It was hypothesised that a considerable pro-
portion of pertussis could have been avoided if all children
had been vaccinated on time [6].
We found that almost one in five children had the pri-
mary pneumococcal series (2nd dose) delayed. These
children may not receive the earliest doses when protec-
tion is needed [17] as full protection is presumably
achieved 2 weeks after the 2nd dose [18]. The incidence of
vaccine type IPD has decreased substantially since the
introduction of pneumococcal vaccines in the Norwegian
programme [18]. However, IPD has been reported in some
cases where the primary doses had been delayed [19, 20].
Delay for measles vaccination, 1st dose, at 29 %, is in line
with other studies ranging from 23 to 57 % [8–10, 21]. It
has been shown that delay may reduce effective vaccine
coverage in young age groups [21]. Delayed measles vacci-
nations keep children susceptible and increase the number
of young children affected during outbreaks as observed
in a recent outbreak in Oslo [4]. During this outbreak,
vaccine failure was rare. Children who should have been
vaccinated according to the schedule, transmitted measles
to children who were too young to receive the vaccine ac-
cording to the Norwegian programme. Hence, improving
the proportion of children following the schedule could be
more effective in protecting young children than recom-
mending measles vaccine at an earlier age. The argument
for timely measles vaccination is further supported by a
recent study showing that delaying MMR vaccination in-
creases the risk of MMR post vaccination seizures [22].
Examining delay for all vaccinations at national level
only, may result in regional differences being overlooked
(range 37–58 %). A wide variation within countries was
also found in a study from low- and middle income coun-
tries [23]. Interestingly, the high proportion of children
with delayed vaccines in some Norwegian counties was
not reflected in the coverage estimates at age 2 years, so
most parents had their children vaccinated. Long travel
time to clinics has been suggested as a reason for delay
[9]. Our study did not focus on geography or remote-
ness. However, delay was common both in the capital
county and in one of the geographically smallest coun-
ties (Vestfold). Hence, a long distance to health care
facilities is probably not a substantial reason for delay,
suggesting other regional barriers such as organisational
and local traditions [23].
The priming with pertussis vaccine (2 doses) and the
1st dose with measles vaccine were considerably delayed
where children were scheduled for vaccination in July
compared to other months of the year. Data on delayed
immunisations in the summer vacation season have to
our knowledge not been presented before. Travelling is
frequent during summer and this may easily spread
measles and pertussis. To avoid susceptibility, parents
should be informed of options of earlier vaccination at
their first visits to well-baby clinics.
A higher proportion of children were delayed for vacci-
nations if they had immigrant parents. This was consistent
with a survey from Flandern, where having a mother born
outside the European Union was a risk factor for childhood
vaccination delay [10]. Delay in minority groups has also
been described elsewhere [8, 9]. Interestingly, we found a
higher risk for delayed pneumococcal and pertussis vaccin-
ation than for delayed measles vaccination in immigrants
compared to non-immigrants. As measles vaccination only
requires one visit in children aged < 2 years, the number of
visits may affect the risk of delay.
Strengths of this study include that our data represent
the vaccination history of all children ≤ 2 years born in
2010 resident in Norway. We showed how data from a
national immunisation registry used to publish annual
coverage estimates could be analysed to improve surveil-
lance by including data on timeliness and delay.
Limitations of our study include that information from
SYSVAK was not linked with NPR. Therefore we do not
have information about unvaccinated children. In
addition, information from SYSVAK and the NPR was
not obtained on the same date and both registries are
regularly updated. We do not believe that this would
have a considerable impact on our results. This assump-
tion is supported by almost identical coverage estimates
for individual vaccines compared to the official Norwe-
gian coverage estimates [11].
Through SYSVAK, we do not know immigrant status,
so our result must be interpreted with caution. However
as 90 % of BCG vaccinated also had 3 doses hepatitis B
vaccine (risk groups are overlapping, but not similar),
BCG vaccination can be used as a proxy parameter to
indicate immigrant children.
Until now, a delay in vaccination according to the
programme results in unnecessarily unprotected chil-
dren, especially for pertussis, that is an endemic dis-
ease, and for measles during outbreaks. A high
vaccination coverage in young children and in the
general population will ensure herd immunity and
some protection for those who are not timely follow-
ing the schedule or are too young to receive vaccina-
tions. However, when introducing a vaccine with age
restrictions, like rotavirus in Norway in autumn
2014, a delay can result in more non-vaccinated chil-
dren since the child might be too old to be offered
the vaccine.
Information focusing on early vaccine protection, more
generous office hours and improved reminder systems, e.g.
text messages or smart phone applications for parents, may
improve timeliness of vaccinations. Every opportunity
should be used to vaccinate and accelerated schedules and
Riise et al. BMC Pediatrics  (2015) 15:180 Page 7 of 8
multiple vaccinations may be used to avoid further delay in
children who have missed out of previous vaccination
opportunities.
Conclusions
Our results show that vaccinations were frequently de-
layed although vaccination coverage was high for vac-
cines targeted at specific diseases. Delay increase
susceptibility for VPD, especially for delayed priming
against pertussis, IPD and measles. Based on the present
infectious disease burden in Norway, the first doses of
pertussis vaccines should be administered on time,
whereas a short delay for measles vaccination is more
acceptable. However, children should not have their
measles vaccinations delayed prior to the summer and
vacation season due to travel and tourism. Knowledge
about delayed vaccination can be used to improve infor-
mation to vaccination providers and parents on the ben-
efits of adhering to age recommendations, that until
now may have been under-communicated. Monitoring
of vaccination delay in addition to coverage is also a use-
ful tool to improve programme surveillance. This is feas-
ible in countries with a national vaccination registry. We
would suggest monitoring of timely and delayed vaccina-
tions also in the future.
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